Cargando…
Can (18)F-PSMA-7Q PET/CT replace prostate biopsy for the diagnosis of prostate cancer?—A single-center retrospective study
BACKGROUND: Of the currently available prostate-specific membrane antigen (PSMA) positron emission tomography (PET) tracers, although (68)Ga-PSMA-11 and (18)F-DCFPyL have been approved by the US Food and Drug Administration (FDA), both tracers are excreted rapidly through the urinary tract, resultin...
Autores principales: | Liu, Yachao, Niu, Shaoxi, Luan, Xiaohui, Zhang, Xiaojun, Liu, Jiajin, Zhang, Jinming, Wang, Ruimin, Xu, Baixuan, Zhang, Xu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906103/ https://www.ncbi.nlm.nih.gov/pubmed/36760865 http://dx.doi.org/10.21037/tau-22-813 |
Ejemplares similares
-
A Pilot Study of (18)F-DCFPyL PET/CT or PET/MRI and Ultrasound Fusion Targeted Prostate Biopsy for Intra-Prostatic PET-Positive Lesions
por: Liu, Yachao, et al.
Publicado: (2021) -
Optimized (68)Ga-Labeled Urea-Based PSMA-Targeted PET Tracers for Prostate Cancer
por: Wu, Yitian, et al.
Publicado: (2022) -
A Preclinical Study of an (125)I-Labeled PSMA Ligand for Prostate-Cancer Puncture
por: Luan, Xiaohui, et al.
Publicado: (2022) -
A Preliminary Study of PSMA Fluorescent Probe for Targeted Fluorescence Imaging of Prostate Cancer
por: Zhou, Haoxi, et al.
Publicado: (2022) -
Targeted fluorescent imaging of a novel FITC-labeled PSMA ligand in prostate cancer
por: Zhou, Haoxi, et al.
Publicado: (2021)